PofoliaShared via Pofolia

European Respiratory Journal· 2013Q1

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Kian Fan Chung, Sally E. Wenzel, Jan Brożek, Andrew Bush et al.

Short summary

New guidelines define severe asthma as uncontrolled asthma despite high-dose controller therapy, including systemic corticosteroids, and provide recommendations for its evaluation and treatment.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Severe asthma is defined by uncontrolled symptoms despite high-dose controller therapy.
  • Guidelines recommend using sputum eosinophil counts and exhaled nitric oxide to guide treatment.
  • Treatment options include anti-IgE antibody, methotrexate, macrolides, antifungals, and bronchial thermoplasty.
  • Severe asthma is recognized as a heterogeneous condition with distinct phenotypes, such as eosinophilic asthma.

AI-generated from the title and abstract; the full text is not read.

Abstract

Severe or therapy-resistant asthma is increasingly recognised as a major unmet need. A Task Force, supported by the European Respiratory Society and American Thoracic Society, reviewed the definition and provided recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults. A literature review was performed, followed by discussion by an expert committee according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach for development of specific clinical recommendations. When the diagnosis of asthma is confirmed and comorbidities addressed, severe asthma is defined as asthma that requires treatment with high dose inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming "uncontrolled" or that remains "uncontrolled" despite this therapy. Severe asthma is a heterogeneous condition consisting of phenotypes such as eosinophilic asthma. Specific recommendations on the use of sputum eosinophil count and exhaled nitric oxide to guide therapy, as well as treatment with anti-IgE antibody, methotrexate, macrolide antibiotics, antifungal agents and bronchial thermoplasty are provided. Coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy.

The authors' abstract, as published at the source. European Respiratory Journal, 2013 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Physiology

PhysiologyMedicine